Investor Relations
BASIC INFORMATION
MEDICOFARMA BIOTECH S.A.
previous name “INBOOK S.A.”
The company is registered at the District Court in Katowice, Commercial Division
KRS No: 0000310188
TAX ID No: 629-21-95-774
REGON No: 277501658
Share capital: 679.783 zł
Dom Maklerski BDM S.A. is acting as the market maker for the Warsaw Stock Exchange – New Connect
President of the Board is responsible for contact with the media and shareholders.
Global leader
in research
Three unique
research platforms
50% of employees
are PhD holders
SHAREHOLDERS
Capital and general share distribution
21,69% – ABS Investment S.A., Beskidzkie Biuro Inwestycyjne S.A.
15,95% – ABS Investment S.A.
5,74% – Beskidzkie Biuro Inwestycyjne S.A.
18,39% – Cezary Kilczewski and Wooller Limited sp. z o.o., Medicofarma S.A. i Vitama S.A.
2,57% – Medicofarma S.A.
15,82% – Vitama S.A.
8,69% – Jakub Dębski
| Shareholder | Number of shares | AGM Votes |
|---|---|---|
| ABS Investment S.A. wraz z Beskidzkie Biuro Inwestycyjne S.A. | 1 474 526 | 21,69% |
| ABS Investment S.A. | 1 084 526 | 15,95% |
| Beskidzkie Biuro Inwestycyjne S.A. | 390 000 | 5,74% |
| Cezary Kilczewski wraz Wooller Limited sp. z o.o., Medicofarma S.A. and Vitama S.A. | 1 249 999 | 18,39% |
| Cezary Kilczewski | 0 | 0,00% |
| Wooller Limited sp. z o.o. | 0 | 0,00% |
| Medicofarma S.A. | 174 518 | 2,57% |
| Vitama S.A. | 1 075 481 | 15,82% |
| Jakub Dębski | 590 467 | 8,69% |
ANNUAL GENERAL MEETING
No Annual General Meeting is planned in the near future
SHARE PRICE
| Na GPW od | 19 kwietnia 2018 |
| Rynek/segment notowań | GPW/Równoległy |
| Sektor (GPW) | Biotechnologia |
| Przynależność do indeksów | WIG-Poland, WIG |
| Ticker GPW | OAT |
| ISIN | PLONCTH00011 |
| Liczba wyemitowanych akcji | 13 670 000 |
SUPERVISORY BOARD AND BOARD
OF MANAGERS
President of the Board
(temporary delegation from the Supervisory Board to act as the Chairman of the Board)
Piotr Zawadzki
Chairman of the Supervisory Board
Piotr Zawadzki
Graduate of the Warsaw University Faculty of Biology, in 1994 received a PhD in Natural Sciences at the Wesleyan University in the US. Since 1995, he lead the department of New Pharmaceutical Technology at Procter & Gamble, subsequently he worked as a Business Development Manager for US Pharmacia and Valeant Pharmaceuticals. He i san author of several scientific publications in prestigious scientific journals.
Members of the Supervisory Board
Piotr Bielecki
Graduate of the Warsaw University of Life Sciences, MA in economics. Since 2003, his work is closely related with the financial market, took up managerial positions at Bank Handlowym, ING Bank Śląski. Member of the Board at Financewell Sp. z o.o. – a company specializing in economic consulting and investment.
Alicja Jabłońska
Graduate of the Warsaw School of Economics, MA in economics. Since 1994, she holds managerial positions in pharmaceutical companies – US Pharmacia, Marcmed, Medicofarma S.A.
Michał Kijek
Graduate of the Maria Courie-Skłodowska University in Lublin, MA in biology. Held managerial positions at Polfa Pharmaceutical Company in Tarchomin and Biowet Bioveterinary Company in Puławy. Since 2004, he acts as the QA Manager (responsible among others for the GMP, ISO, and GLP standards) at Medicofarma S.A. in Radom.
Zbigniew Pawłucki
Boasts 25 years of experience in managing company restructuring, investment management, design and manufacturing. Graduate of the Technische Hohschule in Cologne (Germany), Warsaw Institute of Technology as well as the Academy of Strategic Leadership, Harvard Business Review.